Landscape of Genomic Profiling and Circulating Tumor DNA Among Rare Genitourinary Cancers

IF 2.3 3区医学 Q3 ONCOLOGY

Clinical genitourinary cancer Pub Date : 2024-10-18 DOI:10.1016/j.clgc.2024.102245

Austin G Kazarian, Raj R Bhanvadia, Zine-Eddine Khene, Thomas Gerald, Bailey Brooks, Yair Lotan, Isamu Tachibana, Kris Gaston, Sol Woldu, Vitaly Margulis

{"title":"Landscape of Genomic Profiling and Circulating Tumor DNA Among Rare Genitourinary Cancers","authors":"Austin G Kazarian, Raj R Bhanvadia, Zine-Eddine Khene, Thomas Gerald, Bailey Brooks, Yair Lotan, Isamu Tachibana, Kris Gaston, Sol Woldu, Vitaly Margulis","doi":"10.1016/j.clgc.2024.102245","DOIUrl":null,"url":null,"abstract":"<div><div><ul><li><span>•</span><span><div>Current surveillance and treatment strategies of rare genitourinary cancers are heterogenous and often rely on classical imaging alone leaving opportunity for enhanced surveillance and treatment direction strategies.</div></span></li><li><span>•</span><span><div>Molecular residual disease assessment may offer many benefits to standard modalities including antecedent prediction of recurrence or progression compared to conventional surveillance, early and appropriate identification of patients appropriate for adjuvant treatment, potential for monitoring of treatment response, and adjudication of indeterminate imaging findings.</div></span></li><li><span>•</span><span><div>Comprehensive genomic profiling delineates tumor biology and actionable mutations for personalized medicine in this challenging to treat population including nonclassical targeted agents.</div></span></li></ul></div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"22 6","pages":"Article 102245"},"PeriodicalIF":2.3000,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical genitourinary cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1558767324002155","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

•
Current surveillance and treatment strategies of rare genitourinary cancers are heterogenous and often rely on classical imaging alone leaving opportunity for enhanced surveillance and treatment direction strategies.
•
Molecular residual disease assessment may offer many benefits to standard modalities including antecedent prediction of recurrence or progression compared to conventional surveillance, early and appropriate identification of patients appropriate for adjuvant treatment, potential for monitoring of treatment response, and adjudication of indeterminate imaging findings.
•
Comprehensive genomic profiling delineates tumor biology and actionable mutations for personalized medicine in this challenging to treat population including nonclassical targeted agents.

查看原文本刊更多论文

罕见泌尿生殖系统癌症中基因组图谱和循环肿瘤 DNA 的分布情况

-目前对罕见泌尿生殖系统癌症的监控和治疗策略各不相同，而且通常仅依赖于传统的成像技术，这为加强监控和治疗指导策略留下了机会。-分子残留疾病评估可为标准模式带来许多益处，包括与传统监测相比，可对复发或病情进展进行先期预测、早期适当识别适合辅助治疗的患者、监测治疗反应的潜力以及对不确定的成像结果进行判定。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical genitourinary cancer 医学-泌尿学与肾脏学

CiteScore

5.20

自引率

6.20%

发文量

201

审稿时长

54 days

期刊介绍： Clinical Genitourinary Cancer is a peer-reviewed journal that publishes original articles describing various aspects of clinical and translational research in genitourinary cancers. Clinical Genitourinary Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of genitourinary cancers. The main emphasis is on recent scientific developments in all areas related to genitourinary malignancies. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.